This roundtable series discusses antibody-drug conjugates as therapy for patients with cervical cancer who had progressed on chemotherapy, as discussed by key opinion leaders and participants at virtual live events.
Tisotumab Vedotin Improves Treatment Options in Cervical Cancer
Susan C. Modesitt, MD, discusses the introduction of antibody drug conjugate tisotumab vedotin to treatment for patients with metastatic cervical cancer.
Second-Line Tisotumab Vedotin Shows Durability in Cervical Cancer
In the first article of a 2-part series, Shannon N. Westin, MD, MPH, looks at the promising responses to tisotumab vedotin for patients with recurrent or metastatic cervical cancer.
2 Clarke Drive Cranbury, NJ 08512